Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy

Sabina Sánchez Hernández; Martin Roelsgaard Jakobsen; Rasmus O. Bak

doi:10.3390/ijms231911397

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy

Sabina Sánchez Hernández
, Martin Roelsgaard Jakobsen
, Rasmus O. Bak^*

^*Corresponding author for this work

Department of Biomedicine - Forskning og uddannelse, Skou-bygningen

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

25 Citations (Scopus)

Abstract

Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-specific immune responses could represent an attractive alternative compared to conventional therapeutic approaches in the future, and promising antitumor effects have already been reported in phase I/II clinical trials. Here, we review the many roles of pDCs in cancer and present current advances in developing pDC-based immunotherapeutic approaches for treating cancer.

Original language	English
Article number	11397
Journal	International Journal of Molecular Sciences
Volume	23
Issue	19
ISSN	1661-6596
DOIs	https://doi.org/10.3390/ijms231911397
Publication status	Published - Sept 2022

Keywords

melanoma
pDC-based vaccines
plasmacytoid dendritic cells
tumor-specific immune responses
Dendritic Cells
T-Lymphocytes
Humans
Immunotherapy
Neoplasms/drug therapy
Tumor Microenvironment

Access to Document

10.3390/ijms231911397Licence: CC BY

Library access?

Check availability with the Royal Danish Library

Cite this

@article{b0a30f09110a443cbdaf5dd427d0c41c,

title = "Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy",

abstract = "Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-specific immune responses could represent an attractive alternative compared to conventional therapeutic approaches in the future, and promising antitumor effects have already been reported in phase I/II clinical trials. Here, we review the many roles of pDCs in cancer and present current advances in developing pDC-based immunotherapeutic approaches for treating cancer.",

keywords = "melanoma, pDC-based vaccines, plasmacytoid dendritic cells, tumor-specific immune responses, Dendritic Cells, T-Lymphocytes, Humans, Immunotherapy, Neoplasms/drug therapy, Tumor Microenvironment",

author = "Hern{\'a}ndez, \{Sabina S{\'a}nchez\} and Jakobsen, \{Martin Roelsgaard\} and Bak, \{Rasmus O.\}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/ijms231911397",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences ",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "19",

}

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. / Hernández, Sabina Sánchez ; Jakobsen, Martin Roelsgaard ; Bak, Rasmus O.
In: International Journal of Molecular Sciences , Vol. 23, No. 19, 11397, 09.2022.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy

AU - Hernández, Sabina Sánchez

AU - Jakobsen, Martin Roelsgaard

AU - Bak, Rasmus O.

PY - 2022/9

Y1 - 2022/9

N2 - Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-specific immune responses could represent an attractive alternative compared to conventional therapeutic approaches in the future, and promising antitumor effects have already been reported in phase I/II clinical trials. Here, we review the many roles of pDCs in cancer and present current advances in developing pDC-based immunotherapeutic approaches for treating cancer.

AB - Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells with a wide range of innate and adaptive immunological functions. They constitute the first line of defence against multiple viral infections and have also been reported to actively participate in antitumor immune responses. The clinical implication of the presence of pDCs in the tumor microenvironment (TME) is still ambiguous, but it is clear that pDCs possess the ability to modulate tumor-specific T cell responses and direct cytotoxic functions. Therapeutic strategies designed to exploit these qualities of pDCs to boost tumor-specific immune responses could represent an attractive alternative compared to conventional therapeutic approaches in the future, and promising antitumor effects have already been reported in phase I/II clinical trials. Here, we review the many roles of pDCs in cancer and present current advances in developing pDC-based immunotherapeutic approaches for treating cancer.

KW - melanoma

KW - pDC-based vaccines

KW - plasmacytoid dendritic cells

KW - tumor-specific immune responses

KW - Dendritic Cells

KW - T-Lymphocytes

KW - Humans

KW - Immunotherapy

KW - Neoplasms/drug therapy

KW - Tumor Microenvironment

UR - https://www.scopus.com/pages/publications/85139914712

U2 - 10.3390/ijms231911397

DO - 10.3390/ijms231911397

M3 - Journal article

C2 - 36232698

AN - SCOPUS:85139914712

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 19

M1 - 11397

ER -

Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy

Abstract

Keywords

Access to Document

Library access?

Other files and links

Fingerprint

Cite this